Global ETF Survey 2026: Answer now →
Help us improve your experience. Please confirm your investor type:
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
ETFs with exposure to Tango Therapeutics, Inc. (TNGX)
Invesco DWA Healthcare Momentum ETF - USD This ETF provides exposure to Other US Health Care Equities | 2.64% | +18.18% | +20.89% | +€344K | -€8.6M | €122M | 0.72% | |
|---|---|---|---|---|---|---|---|---|
Virtus LifeSci Biotech Clinical Trials ETF - USD This ETF provides exposure to Equally Weighted US Equities | 1.67% | +17.61% | +33.41% | +€475K | +€6.2M | €45M | 0.65% | |
Invesco DWA SmallCap Momentum ETF - USD This ETF provides exposure to Other Small Cap US Equities | 1.19% | +8.16% | +28.93% | -€733K | -€368M | €393M | 0.6% | |
First Trust Small Cap Growth AlphaDEX Fund ETF - USD This ETF provides exposure to Other Small Cap US Equities | 0.60% | +9.89% | +32.74% | +€41M | +€223M | €1.15B | 0.7% | |
State Street SPDR S&P Biotech ETF - USD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 0.58% | +17.25% | +28.43% | +€768M | +€464M | €9.3B | 0.35% | |
Samsung KODEX SYNTH-US Biotech ETF - KRW This ETF provides exposure to Equally Weighted US Biotechnology Equities | 0.55% | +19.61% | +37.30% | €0 | -€69K | €16M | 0.25% | Not rated |
Global X S&P Biotech ETF - AUD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 0.55% | +21.23% | +23.84% | +€925K | +€212K | €31M | 0.45% | Not rated |
0.43% | +4.95% | +27.47% | +€3.6M | +€100M | €1.34B | 0.6% | ||
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C - USD This ETF provides exposure to Other Equities | 0.43% | +13.10% | +9.81% | €0 | +€2.1M | €8.9M | 0.25% | |
First Trust Small Cap Core AlphaDEX Fund ETF - USD This ETF provides exposure to Other Small Cap US Equities | 0.31% | +8.01% | +28.52% | +€6.1M | +€137M | €1.2B | 0.58% | |
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
